Literature DB >> 15377988

Choroidal melanoma: natural history and management options.

Darren J Bell1, Matthew W Wilson.   

Abstract

BACKGROUND: Choroidal melanoma is the most common primary malignancy of the eye. Enucleation has been the mainstay of treatment, but new and more effective options have recently been proposed as eye- and vision-sparing alternatives.
METHODS: We reviewed the medical literature for trials and case reports involving the evolution, current uses, and limitations of alternatives to enucleation for treating choroidal melanoma.
RESULTS: Options to treat choroidal melanomas depend on the location and size of the tumor and goals of therapy. Local control with plaque radiotherapy has provided overall survival comparable to enucleation. Transscleral resection may leave behind potentially viable melanoma cells following surgery; adjuvant brachytherapy is recommended to irradiate remaining tumor cells. Elevating tissue temperature potentiates the effect of ionizing radiation, thus reducing the dose of radiation needed to treat uveal melanoma. Transpupillary thermotherapy has been effective only in select circumstances, and long-term results have shown poorer local control rates and similar visual outcomes compared with other conservative treatment methods.
CONCLUSIONS: Treatment therapies for choroidal melanoma warrant further study. Currently, enucleation remains as effective as the eye- and vision-sparing approaches.

Entities:  

Mesh:

Year:  2004        PMID: 15377988     DOI: 10.1177/107327480401100503

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  18 in total

1.  Unilateral acute angle closure glaucoma.

Authors:  Shi Zhuan Tan; Keerthika Sampat; Sana Rasool; Daniel Nolan
Journal:  BMJ Case Rep       Date:  2013-02-25

2.  Episcleral brachytherapy for uveal melanoma: analysis of 136 cases.

Authors:  Ciro García-Álvarez; María Antonia Saornil; Francisco López-Lara; Ana Almaraz; María Fe Muñoz; Jesús Frutos-Baraja; Yerena Muiños
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

3.  Cardiac Metastasis of Malignant Melanoma.

Authors:  Abdelhaleem Shawky Hamada; Samah Farouk Abdulla Mohamed; Smitha Anilkumar
Journal:  Heart Views       Date:  2022-07-23

4.  Cardiac Metastases from Choroidal Melanoma.

Authors:  Ammar Madani; Nabil E Omar; Ghulam Mustafa; Mahir Petkar; Samah Mohamed; Maryam Al Kuwari; Sabir Abdul Karim; Reyad Mohsen
Journal:  Clin Case Rep       Date:  2022-07-18

Review 5.  Clinical application of ultra-widefield fundus autofluorescence.

Authors:  Amin Xu; Changzheng Chen
Journal:  Int Ophthalmol       Date:  2020-10-11       Impact factor: 2.031

6.  Role of wide-field autofluorescence imaging and scanning laser ophthalmoscopy in differentiation of choroidal pigmented lesions.

Authors:  Lukas Reznicek; Carmen Stumpf; Florian Seidensticker; Anselm Kampik; Aljoscha S Neubauer; Marcus Kernt
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

7.  Choroidal melanoma suspect. Conservative treatment and evolution. Case report.

Authors:  Mihail Zemba; Radu Alexandru Malciolu
Journal:  Rom J Ophthalmol       Date:  2016 Oct-Dec

Review 8.  Uveal vs. cutaneous melanoma. Origins and causes of the differences.

Authors:  Carolina Belmar-Lopez; Pablo Mancheno-Corvo; Maria Antonia Saornil; Patrick Baril; Georges Vassaux; Miguel Quintanilla; Pilar Martin-Duque
Journal:  Clin Transl Oncol       Date:  2008-03       Impact factor: 3.405

9.  Ocular melanoma: Keep your eyes open for late brain metastases.

Authors:  Danilo O de A Silva; Georgios K Matis; Leonardo F Costa; Matheus A P Kitamura; Eduardo V de C Júnior; Breno J A P Barbosa; Isaac B Santiago; Tatiane I Silva; Fabiana Q de P A Silva; Carlos U Pereira; Hildo R C Azevedo Filho
Journal:  Surg Neurol Int       Date:  2011-10-12

10.  Novel low-kVp beamlet system for choroidal melanoma.

Authors:  Carlos Esquivel; Clifton D Fuller; Robert G Waggener; Adrian Wong; Martin Meltz; Melissa Blough; Tony Y Eng; Charles R Thomas
Journal:  Radiat Oncol       Date:  2006-09-11       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.